Skip to content

Accrued liabilities at other companies

Gilead Sciences logo
Gilead SciencesGILD

Other financials

Income statement

See full
Revenue-
Gross profit-
Operating income-$9.3M-52.6%
Net income-$8.4M-44.6%
EPS (diluted)-$0.05+28.6%

Balance sheet

See full
Cash & equivalents$107.1M+277%
Total debt$871.0K+0.1%
Total equity$107.4M+287%
Total assets$114.2M+227%

Cash flow

See full
Operating cash flow-$8.8M+2.5%

Valuation

See full
Market cap$1.8B+674%
Enterprise value$1.7B+826%

Profitability

See full
Gross margin90%-7.4pp
Operating margin-4,195%-4,591pp
Net margin-4,130.1%-4,444pp
FCF margin-300.5%

Returns & leverage

See full
Return on equity-43.6%-17.9pp
Debt / equity0.0×
Current ratio17.2×+12.6×

Where this comes from

Reported directly by SELLAS Life Sciences Group, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilities.

The official record: SELLAS Life Sciences Group, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about SELLAS Life Sciences Group, Inc.'s accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is SELLAS Life Sciences Group, Inc.'s accrued liabilities?
SELLAS Life Sciences Group, Inc. (SLS) reported accrued liabilities of -$1.26M in Q1 2026.
How has SELLAS Life Sciences Group, Inc.'s accrued liabilities changed year-over-year?
SELLAS Life Sciences Group, Inc.'s accrued liabilities increased by 56.3% year-over-year, from -$2.9M to -$1.26M.
What is the long-term trend for SELLAS Life Sciences Group, Inc.'s accrued liabilities?
Over 2 years (2021 to 2023), SELLAS Life Sciences Group, Inc.'s accrued liabilities has grown at a 41.2% compound annual growth rate (CAGR), from $727K to $1.45M.